Accord Healthcare Pty Ltd

Dostiva and Dexeva are approved for preventing or managing cancer related bone complications and are biosimilars of Xgeva. Denolia and Deskeltia are approved for treating osteoporosis in men and postmenopausal women, as well as bone loss due to cancer therapies or long term glucocorticoid use and are biosimilars of Prolia.

Sondelbay, Teriparintas and Teriparaccord have been approved for the treatment of osteoporosis.